Stocks · Pharmaceuticals

Eli Lilly and Company (LLY)

$1,287.33

+0.64% last session

Market value

$1.20tn

P/E ratio

45.3

Dividend yield

0.75%

52-week range

$806–$1,321

What Eli Lilly and Company does

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity.

Pharmaceuticals · based in the US · listed since 1970Biggest source of revenue: Net product revenue (94%) · breakdownCompany website ↗

Report card

tap a grade for the details

AGrowthGrowing fast

Sales growth, last 12 months49.6% · 100/100

Sales growth a year, 5 years21.6% · 96/100

Earnings per share growth a year, 5 years27.6% · 99/100

AProfitabilityHighly profitable

Net profit margin33.5% · 100/100

Return on equity93% · 100/100

BFinancial strengthStrong

Current ratio (short-term assets ÷ debts)1.35 · 78/100

DValuationLooks expensive

P/E against its own 10-year history50th percentile · 50/100

Free cash flow yield1.1% · 17/100

PEG (P/E ÷ growth)1.6 · 61/100

AMomentumStrong uptrend

Share price, last 12 months55.1% · 100/100

Share price, last 3 months6.5% · 66/100

Price

+55.6% over 1Y

27 Oct 2026$1,285.99

Daily closing prices. Source: Twelve Data.

Bull vs bear

The numbers lean bullish (10 vs 1)

The bull case

A proven grower●●○

Revenue up 12.6% a year for 10 years.

Profit per share compounding●●○

Earnings per share up 26.1% a year.

Growth is speeding up●●○

Revenue growth over the last 12 months (50%) is well above its 5-year average (22%).

Shareholder-friendly management●●○

Passes 3 of 4 capital-allocation checks.

Has always bounced back●○○

Recovered from all 7 past falls of 20%+ in the price history.

Reliable dividend grower●○○

Raised its dividend 9 years in a row.

The bear case

Recoveries can take years●○○

Took 97 months to recover after the 1973 fall.

Can you answer every bear point? Put your answers in your thesis under risks.

See the full picture on Eli Lilly and Company

Ten years of results, revenue by product and region, a management scorecard, bear/base/bull valuations, analyst targets, every SEC filing explained, and a thesis that checks itself after each report. Free.

Create a free account Already a member? Open LLY

Eli Lilly and Company (LLY)

Report card iLearn

Price

Bull vs bear iLearn

See the full picture on Eli Lilly and Company

Bull vs bear iLearn

Report card iLearn

Report card

Bull vs bear

Bull vs bear

Report card